Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

AltheaDx Receives CLIA Certification
AltheaDx, a world leader in the development of companion diagnostics and biopharma services, announced that they have successfully passed the State of California survey for CLIA (Clinical Laboratory Improvement Amendments) certification. AltheaDx is offering high-quality patient and biopharma molecular testing services from their state-of-the-art, GMP, GLP, and now CLIA compliant facility located in the Sorrento Valley, San Diego.
generic viagra online
PTC Therapeutics Initiates Phase 2 Clinical Trial Of PTC299 In Patients With Neurofibromatosis Type 2
PTC Therapeutics, Inc. (PTC) announced the initiation of a Phase 2 clinical trial of PTC299 in adult patients with neurofibromatosis type 2 (NF2), a rare genetic disorder that causes the development of non-malignant brain tumors. PTC299 is a novel, orally administered investigational new drug that is designed to selectively block tumor-related vascular endothelial growth factor (VEGF). With its novel mechanism of action, PTC299 has the potential to meet significant unmet medical need in NF2 and other conditions resulting from the overexpression of VEGF.
News of the day
States Consider Scaling Back Funding For Medicare Drug Benefit Amid Economic Crisis
At least six states have considered eliminating or reducing financial assistance for those enrolled in the Medicare prescription drug benefit program who are affected by the "doughnut hole," or gap in coverage, the AP/Boston Herald reports. According to the AP/Herald, the governors of Rhode Island and Vermont and lawmakers in South Carolina have proposed plans to eliminate such financial assistance programs, while Massachusetts has reduced funding for its program. Meanwhile, proposals in New York and Connecticut to limit financial help have been dismissed.Beneficiaries enrolled in the drug benefit have coverage until total spending reaches $2,700 and then must pay out-of-pocket for their medications until the total spending reaches $4,350, after coverage. At least 16 states provide financial help to beneficiaries who have reached the coverage gap (AP/Boston Herald, 5/27).
Medical Devices

Symposium & Live Announcement Of Genetics And Neuroscience Prize Recipients: Gruber Prize Program 10th Anniversary

July 1, 2009 9:30am - Noon Caspary Auditorium Rockefeller University The Peter and Patricia Gruber Foundation International Prize Program will celebrate its tenth anniversary on July 1, 2009, with an event to be held at Rockefeller University in New York City. The 2009 Gruber Genetics Prize and Neuroscience Prize recipients will be announced live at the event, which will also include a symposium entitled DNA, the Brain, and Society. The discussion will feature a panel of distinguished scientists whose pioneering work is at the forefront of modern genetics and neuroscience: * Dr. David Botstein, 2003 Gruber Genetics Prize laureate and director of the Lewis-Sigler Institute for Integrative Genomics at Princeton University, who has helped lead the revolution in modern genetics with his innovative methods for mapping the human genome and the genes that cause disease, will speak on "The Fruits of the Genome Sequences for Society." * Dr. Linda Buck, associate director of Basic Sciences at the Fred Hutchinson Cancer Research Center, whose research has provided key insights into the mechanisms that underlie the sense of smell in mammals and earned her the Nobel Prize in Physiology or Medicine, will speak on "Deconstructing Smell." * Dr. Fred Gage, professor in the Laboratory of Genetics at the Salk Institute and recipient of the Max Planck Research Prize, whose work may eventually make possible the replacement or enhancement of brain and spinal cord tissue lost or damaged due to neurodegenerative disease or trauma, will speak on "Brain Plasticity and Diversity." * Dr. Solomon Snyder, professor in the Department of Neuroscience at Johns Hopkins University Medical School, whose discoveries about communication mechanisms within and between brain cells earned him the National Medal of Science, will speak on "Novel Neural Messengers Impacting Neural Diseases." The Gruber Prize Program began in 2000 with the Cosmology Prize and was expanded thereafter with the Genetics and Justice Prizes added in 2001, the Women Rights Prize in 2003, and the Neuroscience Prize in 2004. The Program honors contemporary individuals whose groundbreaking work in those five fields provides new models that inspire and enable fundamental shifts in knowledge and culture. The Selection Advisory Boards choose individuals whose contributions in their respective fields advance our knowledge, potentially have a profound impact on our lives, and, in the case of the Justice and Women"s Rights Prizes, demonstrate courage and commitment in the face of significant obstacles. Alyson O"Mahoney Robin Leedy & Associates, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009